Vitamin K1 supplementation to improve the stability of anticoagulation therapy with vitamin K antagonists: A dose-finding study

Haematologica

Volumn 96, Issue 4, 2011, Pages 583-589

  Gebuis, Edward P A ^a   Rosendaal, Frits R ^a   van Meegen, Erik ^b   van der Meer, Felix J M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Medial Anticoagulation Clinic   (Netherlands)

Author keywords

Anticoagulation stability; Dose finding; Supplementation; Therapeutic range; Vitamin K1

Indexed keywords

ACENOCOUMAROL; PHENPROCOUMON; PHYTOMENADIONE; PLACEBO; ANTICOAGULANT AGENT; ANTIFIBRINOLYTIC AGENT;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOSE CALCULATION; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; INTRAOCULAR HEMORRHAGE; LOW DRUG DOSE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPTIMAL DRUG DOSE; RANDOMIZED CONTROLLED TRIAL; VENOUS THROMBOEMBOLISM; CLINICAL TRIAL; DIET SUPPLEMENTATION; DRUG ANTAGONISM; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ANTIFIBRINOLYTIC AGENTS; DIETARY SUPPLEMENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME; VITAMIN K 1; YOUNG ADULT;

EID: 79953871008     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2010.035162     Document Type: Article

References (22)

1. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 Suppl):160S-198S.
2. Reynolds MW, Fahrbach K, Hauch O, Wygant G, Estok R, Cella C, et al. Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and metaanalysis. Chest. 2004;126(6):1938-1945.
3. Shalev V, Rogowski O, Shimron O, Sheinberg B, Shapira I, Seligsohn U, et al. The interval between prothrombin time tests and the quality of oral anticoagulants treatment in patients with chronic atrial fibrillation. Thromb Res. 2007;120(2):201-206.
4. Van Walraven C, Oake N, Wells PS, Forster AJ. Burden of potentially avoidable anticoagulant-associated hemorrhagic and thromboembolic events in the elderly. Chest. 2007;131(5):1508-1515.
5. Levine MN, Raskob G, Beyth RJ, Kearon C, Schulman S. Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 Suppl):287S-310S.
6. Cushman M, Booth SL, Possidente CJ, Davidson KW, Sadowski JA, Bovill EG. The association of vitamin K status with warfarin sensitivity at the onset of treatment. Br J Haematol. 2001;112(3):572-577.
7. Franco V, Polanczyk CA, Clausell N, Rohde LE. Role of dietary vitamin K intake in chronic oral anticoagulation: prospective evidence from observational and randomized protocols. Am J Med. 2004;116(10): 651-656.
8. Khan T, Wynne H, Wood P, Torrance A, Hankey C, Avery P, et al. Dietary vitamin K influences intra-individual variability in anticoagulant response to warfarin. Br J Haematol. 2004;124(3):348-354.
9. Sconce E, Khan T, Mason J, Noble F, Wynne H, Kamali F. Patients with unstable control have a poorer dietary intake of vitamin K compared to patients with stable control of anticoagulation. Thromb Haemost. 2005;93(5):872-875.
10. Schurgers LJ, Shearer MJ, Hamulyak K, Stocklin E, Vermeer C. Effect of vitamin K intake on the stability of oral anticoagulant treatment: dose-response relationships in healthy subjects. Blood. 2004;104(9): 2682-2689.
11. Sconce E, Avery P, Wynne H, Kamali F. Vitamin K supplementation can improve stability of anticoagulation for patients with unexplained variability in response to warfarin. Blood. 2007;109(6):2419-2423.
12. Rombouts EK, Rosendaal FR, van der Meer FJ. Daily vitamin K supplementation improves anticoagulant stability. J Thromb Haemost. 2007;5(10):2043-2048.
13. Ford SK, Moll S. Vitamin K supplementation to decrease variability of International Normalized Ratio in patients on vitamin K antagonists: a literature review. Curr Opin Hematol. 2008;15(5): 504-508.
14. Rombouts EK, Rosendaal FR, van der Meer FJ. The effect of vitamin K supplementation on anticoagulant treatment. J Thromb Haemost. 2006;4(3):691-692.
15. Pattacini C, Manotti C, Pini M, Quintavalla R, Dettori AG. A comparative study on the quality of oral anticoagulant therapy (warfarin versus acenocoumarol). Thromb Haemost. 1994;71(2):188-191.
16. Barcellona D, Vannini ML, Fenu L, Balestrieri C, Marongiu F. Warfarin or acenocoumarol: which is better in the management of oral anticoagulants? Thromb Haemost. 1998;80(6):899-902.
17. Gadisseur AP, van der Meer FJ, Adriaansen HJ, Fihn SD, Rosendaal FR. Therapeutic quality control of oral anticoagulant therapy comparing the short-acting aceno-coumarol and the long-acting phenpro-coumon. Br J Haematol. 2002;117(4): 940-946.
18. Fihn SD, Gadisseur AA, Pasterkamp E, van der Meer FJ, Breukink-Engbers WG, Geven-Boere LM, et al. Comparison of control and stability of oral anticoagulant therapy using acenocoumarol versus phen-procoumon. Thromb Haemost. 2003;90 (2):260-266.
19. Laporte S, Quenet S, Buchmuller-Cordier A, Reynaud J, Tardy-Poncet B, Thirion C, et al. Compliance and stability of INR of two oral anticoagulants with different half-lives: a randomised trial. Thromb Haemost. 2003;89(3):458-467.
20. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993;69(3):236-239.
21. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihe-mostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692-694.
22. Van Leeuwen Y, Gebuis EPA, van der Meer FJM, and Rosendaal FR. Late breaking clinical trial: a randomized comparison of the quality of anticoagulant therapy with two vitamin K antagonists: warfarin versus phenprocoumon [abstract]. J Thromb Haemost. 2009;7:1202-1204. Abstract LB-MO-001.